XLRN News and Press, Acceleron Pharma Inc. From 11/06/19

– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfusion independence for ≥ 8 weeks and median total duration of clinical benefit was 83.6 weeks fo...

Acceleron Pharma (NASDAQ: XLRN ): Q3 GAAP EPS of -$0.86 misses by $0.04 . Revenue of $4.21M (+29.1% Y/Y) misses by $0.23M . Press Release More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news,

- FDA’s review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing - - Six clinical abstracts accepted for presentation at the 61 st American Society of Hematology (ASH) Annual Meeting - Acceleron Pharma Inc. (Nasdaq:XLRN), a leading...

AES , ALE , AMRX , ANIP , AYR , BCOR , BKI , BLMN , BR , CARS , CBRE , CNHI , CNR , COTY , CPRI , CRCM , CRL , CSTE , CVIA , CVS , CWEN , CYBR , DEA , DNOW , DOC , ELAN , ENBL , ESPR , FUN , GCP , GEL , GIB , GLOG , GOLD , HUM , HZNP , IMOS , IONS , JE...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, November 6, 2019 at 10:00 a.m. EST to discuss its third quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Inves...

Shares of Acceleron Pharma (NASDAQ: XLRN) fell 12% in September, according to data provided by S&P Global Market Intelligence , after the biotech reported disappointing results for its drug candidate ACE-083 in patients who have facioscapulohumeral muscular dystrophy (FSHD). Interestin...

Getting new drugs to market can be a tough business. Acceleron Pharma (NASDAQ: XLRN) is learning this the hard way, scrapping plans to continue development for its experimental drug, ACE-083, in treating patients who have facioscapulohumeral muscular dystrophy (FSHD).  The drug showed ...

Citing disappointing results from a Phase 2 study, Acceleron Pharma (NASDAQ: XLRN ) will terminate development of ACE-083 for facioscapulohumeral muscular dystrophy. More news on: Acceleron Pharma Inc., Healthcare stocks news, Stocks on the move, Read more ...

– ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline results from the Phase 2 trial...

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to s...